Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD5213 + pregabalin
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AZD5213 + pregabalin is a combination of two investigational and approved drugs evaluated for the treatment of painful diabetic neuropathy. AZD5213 is a potent, competitive, rapidly reversible functional antagonist (inverse agonist) at the human histamine H3 receptor. It increases the release of neurotransmitters such as histamine, acetylcholine, dopamine, and norepinephrine in preclinical models and has shown activity in reversing neuropathic pain in rodents[1][5]. Pregabalin is an approved gabapentinoid that binds to the α2δ subunit of voltage-gated calcium channels in the central nervous system, reducing excitatory neurotransmitter release and providing antinociceptive (pain-reducing) and anticonvulsant effects[6][8]. The combination was studied by AstraZeneca for efficacy in treating painful diabetic neuropathy but did not demonstrate clinical benefit over placebo or monotherapy with pregabalin[4][5][7].
- Other names
- AZD5213 + Lyrica
02
Targets
HRH3 (Histamine Receptor H3)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)CACNA2D2 (α2δ-2)
Beyond the preview
Go deeper on AZD5213 + pregabalin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD5213 + pregabalin.